GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNN) » Definitions » Book Value per Share

Clene (CLNN) Book Value per Share : $0.03 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Clene Book Value per Share?

Clene's book value per share for the quarter that ended in Mar. 2024 was $0.03.

During the past 3 years, the average Book Value Per Share Growth Rate was 158.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Clene was 158.80% per year. The lowest was 158.80% per year. And the median was 158.80% per year.

Clene's current price is $0.351. Its book value per share for the quarter that ended in Mar. 2024 was $0.03. Hence, today's PB Ratio of Clene is 10.64.

During the past 5 years, the highest P/B Ratio of Clene was 2375.00. The lowest was 1.74. And the median was 14.68.


Clene Book Value per Share Historical Data

The historical data trend for Clene's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene Book Value per Share Chart

Clene Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
-3.87 0.01 0.20 0.04 0.10

Clene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 0.17 0.17 0.10 0.03

Competitive Comparison of Clene's Book Value per Share

For the Biotechnology subindustry, Clene's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clene's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clene's PB Ratio distribution charts can be found below:

* The bar in red indicates where Clene's PB Ratio falls into.



Clene Book Value per Share Calculation

Clene's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(13.39-0.00)/128.42
=0.10

Clene's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(4.26-0.00)/128.43
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Clene  (NAS:CLNN) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Clene Book Value per Share Related Terms

Thank you for viewing the detailed overview of Clene's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Clene (CLNN) Business Description

Traded in Other Exchanges
Address
6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).
Executives
David J Matlin director
Matthew Kiernan director 500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Arjun Jj Desai director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Robert Dee Etherington director, officer: Chief Executive Officer 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
John Henry Stevens director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Chidozie Ugwumba director 158 FILMORE STREET, DENVER CO 80206
Alison Mosca director 26 PATRIOT PLACE, SUITE 301, FOXBORO MA 02035
Jonathon Gay director 177 HUNTINGTON AVENUE, 21ST FLOOR, BOSTON MA 02115
General Resonance Llc 10 percent owner 6510 SOUTH MILLROCK DRIVE, SUITE 250, HOLLADAY UT 84121
Robert Glanzman officer: Chief Medical Officer 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Morgan R Brown officer: Chief Financial Officer 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Vallerie Mclaughlin director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Mark Mortenson officer: Chief Science Officer 500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Fiona Costello director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Shalom Jacobovitz director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121